Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), which affects hundreds of millions globally [1][2] - The trial's primary focus is on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to determine its potential in reducing alcohol cravings and consumption [2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Market Potential - The substance use disorder treatment market in the U.S. was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, indicating a significant opportunity for innovative treatments like CMND-100 [3]

Core Insights - Clearmind Medicine Inc. is advancing its mission to develop psychedelic-derived therapeutics by engaging a prominent government and political affairs consulting firm to navigate regulatory landscapes and promote acceptance among U.S. policymakers [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing novel psychedelic-derived therapeutics aimed at addressing major under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, necessitating informed regulatory frameworks to facilitate the integration of these therapies into mainstream healthcare [2][3] - Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for alcohol use disorder at prestigious institutions, including Yale School of Medicine and Johns Hopkins University [3]

Core Viewpoint - Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center as a clinical site, following the enrollment of the first patient [1][3]. Group 1: Clinical Trial Expansion - The addition of Tel Aviv Sourasky Medical Center, led by Dr. David Zeltser, enhances the trial's capacity to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile [2]. - Other prestigious institutions involved in the trial include Yale School of Medicine and Johns Hopkins University, indicating a strong clinical network [2][3]. Group 2: Company Objectives and Focus - Clearmind is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues, particularly AUD, which affects millions and is responsible for 2.6 million deaths annually [3][4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents to strengthen its position [5].

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | April 30, | | October 31, | | --- | --- | --- | --- | | | 2025 | | 2024 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 4,472,520 | | $ 6,573,813 | | Other ...

Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind's intellectual portfolio currently consists of 19 patent families including 31 granted patents. For furt ...

Patent publication in Europe strengthens Clearmind's global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the official publication of a European patent application by the European Pate ...

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. leading to the filing of a new international patent application for a treatment targeting anorexia, bulimia, and other eating disorders [1][2] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4] Collaboration Details - The patent application involves the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide (PEA), aiming to address neurobiological and psychological factors associated with eating disorders [2] Industry Context - Eating disorders are serious mental health conditions affecting up to 70 million people globally, with a prevalence increase from 3.4% to 7.8% between 2000 and 2018 [3] - These disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders [3] Clearmind Medicine Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a proprietary treatment targeting anorexia, bulimia, and other eating disorders, highlighting its commitment to developing innovative therapies for under-treated mental health conditions [1][4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant health issues, including eating disorders and alcohol use disorder [5]. - The company currently holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [6]. Treatment Development - The new patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA), targeting the neurobiological and psychological factors associated with eating disorders [2]. - The company aims to provide new treatment options for individuals struggling with eating disorders through the therapeutic potential of 3-MMC and PEA [4]. Industry Context - Eating disorders are serious mental health conditions that significantly impact health, emotions, and daily functioning, with up to 70 million people affected globally [3]. - The prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, indicating a growing public health concern [3].